Compare TransMedics Group Inc (TMDX) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Materials Select Sector SPDR Fund — how do they compare? TransMedics Group Inc trades at $77.34 (market cap $2.74B), while Materials Select Sector SPDR Fund trades at $49.51 (market cap $7.73B). The key difference: Materials Select Sector SPDR Fund is far larger — about 2.8× TransMedics Group Inc's market cap, and Materials Select Sector SPDR Fund is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Materials Select Sector SPDR Fund for 70 Days on average.
| TMDX | XLB | |
|---|---|---|
Market Cap | $2.74B | $7.73B |
Volume | 949,331 | 13,681,146 |
Sector | Health | — |
52-Week High | $150.42 | $53.67 |
52-Week Low | $61.99 | $42.23 |
Typical Hold Time | 24 Days | 70 Days |
Enterprise Value | $3.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
XLB trades at $49.49, up 1.04% with a bearish technical signal from moving averages. The materials ETF shows neutral oscillators but faces selling pressure with ADX indicators signaling strong trends. Recent news highlights sector concentration risks with chemicals comprising 49% of assets, while infrastructure and manufacturing trends provide support. The ETF remains below its 200-day moving average of $50.93, indicating technical weakness.
Outlook remains cautious as materials sector faces cyclical headwinds with limited upside after recent rebound. Investment opportunity exists in AI-resistant businesses and infrastructure exposure, but risks include heavy concentration in chemicals and moderate overvaluation in construction materials. Wall Street sentiment appears mixed with some analysts viewing current levels as fully valued.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
